Vision and values
ANZCHOG’s vision is to ensure that all children and adolescents with cancer and associated blood diseases are provided with the highest quality, evidence-based care to ensure optimal outcomes in terms of survivorship and quality of life.
ANZCHOG’s core values are excellence, compassion, commitment and collaboration. All activities are underpinned by evidence-based practice and adherence to high ethical standards.
ANZCHOG’s primary purpose is to improve outcomes for children and adolescents with cancer and associated blood diseases through quality research, facilitation of innovative paediatric clinical trials and promotion of best practice in clinical care.
ANZCHOG also has a role in facilitating:
- education and advancement of knowledge in all aspects of care and treatment of children and adolescents with cancer and associated blood disorders
- advocacy and leadership in the field of childhood and adolescent blood diseases and cancer.
We are a small team who work with our extensive multi-disciplinary membership, with the goal of improving treatment and care, striving to ensure optimal outcomes in terms of survivorship and quality of life.
The Australian and New Zealand Children’s Cancer Study Group was established in 1986, which was changed to ANZCHOG in 2003 to reflect the inclusion of blood diseases as a major group of the patients under our care.
In 2007, ANZCHOG secured on-going Commonwealth Government funding through Cancer Australia’s Support for Cancer Clinical Trials program. This support provided essential core infrastructure funding, which directly accelerated our ability to coordinate ANZCHOG’s clinical trial activity. Since then, we have continued to grow, partnering with a range of government, philanthropy and charity groups, to develop new trials and bring more international trials to Australia and New Zealand. Importantly, we are building centralised trial capacity within the ANZCHOG Office, working closely with all children’s cancer centres in Australia and New Zealand, and collaborating with international trials groups through Europe, United Kingdom, USA and Canada.